Claims
- 1. A compound of the formula ##STR13## wherein X is O, S, CH.sub.2, N-lower alkyl or N-lower alkyl carboxyacyl, each alkyl of one to six carbon atoms, inclusive;
- R.sub.3 is hydrogen, halogen, methyl, 2,6-dimethyl, 3,5-dimethyl, -CHO, -CH.sub.2 OH, -CH(CH.sub.3)OH, -CH.sub.2 SCH.sub.3, or pyrrolidino;
- R.sub.4 is ##STR14## and pharmaceutically acceptable acid addition salts thereof.
- 2. A compound of claim 1 wherein R.sub.4 is ##STR15##
- 3. A compound of claim 1 wherein R.sub.4 is ##STR16##
- 4. A compound of claim 1 wherein R.sub. 4 is ##STR17##
- 5. A compound of claim 1 wherein R.sub.4 is ##STR18##
- 6. A compound of claim 1 wherein R.sub.4 is ##STR19##
- 7. A compound of claim 1 wherein R.sub.4 is ##STR20##
- 8. The compound according to claim 1, N,(p-[1-adamantyloxy]phenyl)pyrrolidine.
- 9. The compound according to claim 1, 1-(.alpha.-1-adamantyl-p-tolyl)pyrrolidine.
- 10. The compound according to claim 1, 1-(p-1-adamantylthiophenyl)pyrrolidine.
- 11. The compound according to claim 1, N-(p-[2,2,2-bicyclooctyloxy)phenyl)pyrrolidine.
- 12. The compound according to claim 1, N-[4-(1-adamantyloxy)-3-chlorophenyl]pyrrolidine.
- 13. The compound according to claim 1, N-[4-(1-adamantyloxy)-3,5-dimethylphenyl]pyrrolidine.
- 14. The compound according to claim 1, 1-[4-(adamantyloxy)-2-fluorophenyl]pyrrolidine.
- 15. The compound according to claim 1, 1-[4-(1-adamantyloxy)-2,6-dimethylphenyl]pyrrolidine.
- 16. The compound according to claim 1, 1-[4-(1-diamantyloxy)phenyl]pyrrolidine.
- 17. The compound according to claim 1, N-[4-(1-adamantyloxy)phenyl]pyrrolidine hydrochloride.
- 18. The compound according to claim 1, [4-(1-adamantyloxy)-3-fluorophenyl]pyrrolidine.
- 19. A pharmaceutical dosage unit form adapted to oral administration to obtain hypolipidemic or hypocholesteremic effects consisting essentially of an effective amount for said effects of a compound selected from those of claim 1 in combination with pharmaceutical means which adapt the compound for oral administration.
- 20. The composition of claim 19 wherein said compound is N-[p-(1-adamantyloxy)phenyl]pyrrolidine.
- 21. A method of obtaining hypolipidemic or hypocholesteremic effects in a mammal which consists essentially of administering orally to said mammal a pharmaceutical dosage unit form supplying an effective amount for hypolipidemic or hypocholesteremic effect of a compound selected from those of claim 1.
- 22. The method of claim 21 wherein the amount of compound administered is within the range of from about 0.1 to about 10 grams on a daily basis.
- 23. The method of claim 21 wherein said compound is N-[4(1-adamantyloxy)-2-fluorophenyl]pyrrolidine.
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of application Ser. No. 507,462, filed Sept. 19, 1974, which is a continuation-in-part of application Ser. No. 416,402, filed Nov. 16, 1973 both abandoned.
US Referenced Citations (9)
Non-Patent Literature Citations (2)
Entry |
Szinai et al.; Chem. Ab. vol. 72, 66496j, (1970). |
Chakrabarti et al.; Chem. Ab. vol. 70, 57242e (1969). |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
507462 |
Sep 1974 |
|
Parent |
416402 |
Nov 1973 |
|